Sibeprenlimab  (Synonyms: 西贝瑞单抗; VIS649)

Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN)^[1][2][3].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

TNFSF13/APRIL/CD256

Sibeprenlimab (VIS649, 10, 50 μg/mL，5 天) 抑制 APRIL 介导的 Na ve (CD43-) 小鼠 B 细胞增殖，以及 RPMI 8226 和 JJN3 细胞的存活^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Sibeprenlimab (VIS649, 0.5-25 mg/kg/周，静脉注射，4-8 周) 可选择性降低食蟹猴的血清 IgA 水平^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

8741  [NCBI]

O75888

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.36 kDa

2382896-07-1

液体

Colorless to light yellow

西贝瑞单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• 
  Immobilized APRIL/TNFSF13 Trimer Protein, Human (HEK293, His-Flag, HY-P70733A) can bind Sibeprenlimab. The EC₅₀ for this effect is 5.059 ng/mL.

• [1]. Mohit Mathur, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep. 2022 Feb 8;7(5):993-1003.  [Content Brief]

  [2]. Mathur M, et al. A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence. J Clin Med. 2023 Nov 4;12(21):6927.  [Content Brief]

  [3]. Refardt J, et al. Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. N Engl J Med. 2023 Nov 16;389(20):1877-1887.  [Content Brief]

  [4]. Myette JR, et al. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 2019 Jul;96(1):104-116.  [Content Brief]